Complications Following Percutaneous Mitral Valve Repair

Livia Gheorghe, Alfonso Ielasi, Benno J.W.M. Rensing, Frank D. Eefting, Leo Timmers, Azeem Latib, Martin J. Swaans

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Mitral valve disease affects more than 4 million people in the United States and it is the second most prevalent valvulopathy in Europe. The gold standard of treatment in these patients is surgical repair or mitral valve replacement. In the last decade, numerous transcatheter therapies have been developed to overcome the increased number of subjects with symptomatic severe mitral regurgitation and high surgical risk. The Mitraclip (Abbott Vascular, Menlo Park, CA), PASCAL (Edwards Lifesciences, Irvine, CA, USA), the Carillon™ Mitral Contour System™ (Cardiac Dimension Inc., Kirkland, WA, USA), the Mitralign™ (Mitralign, Tewksbury, Massachusetts), and the Cardioband (Edwards Lifesciences, Irvine, CA) are the principal percutaneous devices for mitral valve repair. We present an evidence-based clinical update that provides an overview of these technologies and their potential complications.

Original languageEnglish (US)
Article number146
JournalFrontiers in Cardiovascular Medicine
StatePublished - Oct 18 2019


  • Cardioband
  • Carillon device
  • MitraClip®
  • Mitralign
  • complications
  • mitral valve (MV) repair
  • transcatheter interventions

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Complications Following Percutaneous Mitral Valve Repair'. Together they form a unique fingerprint.

Cite this